AstraZeneca PLC logo


AstraZeneca PLC


Earnings Summary

Net Profits
Net Profit Margins



AstraZeneca PLC’s revenue jumped 11.08% since last year same period to $6417Mn in the Q4 2018. On a quarterly growth basis, AstraZeneca PLC has generated 20.17% jump in its revenue since last 3-months.

Net Profits:

AstraZeneca PLC’s net profit fell -20.52% since last year same period to $1034Mn in the Q4 2018. On a quarterly growth basis, AstraZeneca PLC has generated 139.91% jump in its net profits since last 3-months.

Net Profit Margins:

AstraZeneca PLC’s net profit margin fell -28.45% since last year same period to 16.11% in the Q4 2018. On a quarterly growth basis, AstraZeneca PLC has generated 99.64% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AstraZeneca PLC post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

AstraZeneca PLC’s earning per share (EPS) estimates for the current quarter stand at 0.88 - a 23.27% jump from last quarter’s estimates.

EPS Estimate Current Year:

AstraZeneca PLC’s earning per share (EPS) estimates for the current year stand at 0.88.

Key Ratios

Key ratios of the AstraZeneca PLC post its Q1 2023 earnings

Earning Per Share (EPS)
Dividend Per Share (DPS)


Earning Per Share (EPS):

AstraZeneca PLC’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2023. This indicates that the AstraZeneca PLC has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Dividend Per Share (DPS):

AstraZeneca PLC declared 0.99 dividend per share during the earnings announcement for Q1 2023.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca plc - ADR has a market cap of $202.1 Billion. It has a P.E ratio of 61.46. The shares of Astrazeneca plc - ADR are trading at $66.74. .

AstraZeneca PLC
1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Health Technology
Pascal Soriot

Trading and brokerage services provided by

Alpaca iconDrivewealth icon

Banking and Remittance services provided by

SBM icon

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*